Healthcare - Biotechnology - NASDAQ - US
$ 3.85
-1.79 %
$ 414 M
Market Cap
-3.35
P/E
CASH FLOW STATEMENT
-118 M
OPERATING CASH FLOW
41.4 M
INVESTING CASH FLOW
82.4 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Tango Therapeutics, Inc.
| Net Income | -102 M |
| Depreciation & Amortization | 2.42 M |
| Capital Expenditures | -1.53 M |
| Stock-Based Compensation | 19.1 M |
| Change in Working Capital | -38 M |
| Others | -38 M |
| Free Cash Flow | -120 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (101.7) | (108.2) | (58.2) | (52.0) | (14.1) |
| Depreciation & Amortization | 2.4 | 1.6 | 0.9 | 0.7 | 0.6 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 19.1 | 14.2 | 7.8 | 1.8 | 1.7 |
| Other Operating Activities | 0.2 | 1.8 | 1.3 | 0.9 | (14.7) |
| Change in Working Capital | (38.0) | (18.5) | (11.3) | 118.7 | 1.7 |
| Cash From Operations | (118.0) | (109.1) | (59.5) | 70.1 | (24.8) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (1.5) | (7.7) | (1.8) | (1.1) | (1.8) |
| Other Items | 43.0 | 34.1 | (181.6) | (144.4) | 2.7 |
| Cash From Investing Activities | 41.4 | 26.4 | (183.4) | (145.5) | 0.8 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 342.1 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.4 | 1.6 | 15.2 | 80.9 | 11.0 |
| Cash From Financing Activities | 82.4 | 1.6 | 357.3 | 80.9 | 11.0 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 5.8 | (81.1) | 114.4 | 5.5 | 25.2 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (119.5) | (116.8) | (61.4) | 69.0 | (26.6) |